Articles related to CHEMOTHERAPY

Neoadjuvant nivolumab plus chemotherapy improved event-free survival and increased the proportion of patients who had a pathological complete response in patients with resectable NSCLC compared to chemotherapy alone. Nivolumab was added to neoadjuvant chemotherapy, but neither the incidence of side effects nor the viability of surgery was affected.

The researchers believe these are the first data to compare FGFR-directed therapy with chemotherapy in patients with FGFR-altered UC, demonstrating comparable efficacy and manageable safety. Experimentation revealed that FGFR3 DNA alterations in conjunction with FGFR1/3 mRNA overexpression may be better predictors of rogaratinib response.

Even with superior frontline therapy using A+CHP, this exploratory study suggests that consolidative SCT should be considered in CD30+ peripheral T-cell lymphoma (PTCL) patients. More large-scale studies are needed, especially in DUSP22-rearranged and low International Prognostic Index ALK ALCL, to determine whether there are favorable subgroups that could be treated with A+CHP alone.

First-line pembrolizumab and pembrolizumab-chemotherapy continued to outperform cetuximab-chemotherapy in recurrent/metastatic head and neck squamous cell carcinoma after a 4-year follow-up. Following pembrolizumab-based therapy, patients responded well to subsequent treatment.

The hyperfractionated cyclophosphamide, vincristine, doxorubicin, and dexamethasone(hyper-CVAD) regimen has undergone many modifications to make administration more palatable and user-friendly for patients and physicians in community and academic settings, including refinements to avoid complications and reduce adverse events. Dr. Elias Jabbour of MD Anderson Cancer Center reviews a number of these modifications in this interview.

In patients with advanced-stage, untreated follicular lymphoma (FL), the RELEVANCE trial demonstrated that rituximab plus chemotherapy (R-chemo) and lenalidomide plus rituximab (R2) had comparable efficacy (FL). After six years of follow-up, a report on the second interim analysis of the RELEVANCE experiment is presented here.